AARD Stock Analysis: Buy, Sell, or Hold?
AARD - Aardvark Therapeutics, Inc. Common Stock
$5.70
0.08 (1.42%)
▲
5d:
+12.65%
30d:
+43.58%
90d:
+39.36%
WAIT
LOW Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Get Alerted When AARD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: AARD is 15.9% above its trading range ($4.92). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: AARD is 15.9% above its trading range ($4.92). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: AARD is currently trading at $5.70, which is considered extended relative to its 30-day fair value range of $3.58 to $4.92.
Technical Outlook: Technically, AARD is in a strong downtrend. Immediate support is located at $3.71, while resistance sits at $5.99.
Market Sentiment: AARD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (7th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $15.44 (+171.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AARD is in a strong downtrend. Immediate support is located at $3.71, while resistance sits at $5.99.
Market Sentiment: AARD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (7th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $15.44 (+171.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.58 -
$4.92
Company Quality Score
59/100
(HOLD)
Options IV Signal
7th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
62.5%
All Signals
- BEARISH: Price significantly overextended (+15.9% above its trading range)
- BULLISH: Options cheap (IV 7th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 171.0% below Wall St target ($15.44)
- WARNING: Recommendation downgraded due to 15.9% overvaluation
Trading Range Analysis
30-Day Trading Range
$3.58 -
$4.92
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$1.27
(22.2%)
Support & Resistance Levels
Support Level
$3.71
Resistance Level
$5.99
Current Trend
Strong Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.76
Wall Street Target
$15.44
(+171.0%)
Share & Embed Analysis
Last updated: July 02, 2026 9:40 PM ET
Data refreshes hourly during market hours. Next update: 10:40 PM
Data refreshes hourly during market hours. Next update: 10:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AARD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 63 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1041 | 62 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 63 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$106 | 64 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
